Drug Profile
CT 3578
Latest Information Update: 09 Mar 2010
Price :
$50
*
At a glance
- Originator Cell Therapeutics
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders; Transplant rejection
Most Recent Events
- 18 May 2001 No-Development-Reported for Immunological disorders in USA (Unknown route)
- 18 May 2001 No-Development-Reported for Transplant rejection in USA (Unknown route)
- 11 Nov 1996 Preclinical development for Immunological disorders in USA (Unknown route)